Kenox Pharmaceuticals

Name

Kenox Pharmaceuticals

Legal name

Kenox Pharmaceuticals Inc.

Website

https://kenoxpharma.us

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Contract pharmaceutical manufacturing
• Inhaled nasal drug products
• Clinical fill-finish services
• GMP analytical testing
• Bioequivalence testing

Headquarters

HQ city

Monmouth Junction

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development and Manufacturing Services: CDMO services providing formulation development, manufacturing, and analytical testing for orally inhaled and nasal drug products for Phase I and Phase II clinical trials. Revenue generated through project-based contracts with pharmaceutical companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Kenox Pharmaceuticals is a specialty contract development and manufacturing organization (CDMO) that provides formulation development, small-scale clinical manufacturing, and GMP analytical testing for orally inhaled and nasal drug products (OINDPs), including drug-device combinations for inhaled, nasal, and ophthalmic routes. Its services are targeted at pharmaceutical companies developing Phase I and Phase II assets in CNS, pulmonary, and rare disease indications.

Product overview

Kenox Pharmaceuticals is a specialized contract development and manufacturing organization (CDMO) focused on orally inhaled and nasal drug products (OINDPs). The company offers two interconnected core offerings: OINDP manufacturing services supporting small-scale fill-finish operations for Phase I and II clinical trials with batch sizes from hundreds to a few thousand units, and GMP analytical testing services including in vitro bioequivalence (IVBE) testing. These capabilities are designed to support drug development programs across therapeutic areas including CNS indications, pulmonary conditions, and rare diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Orally Inhaled and Nasal Drug Products (OINDPs) Manufacturing Services
• GMP Analytical Testing Services

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Strides Pharma Science Ltd.coreStrategic or Co-development Partner · 9 September 2025Strides Pharma Science Ltd., through its wholly owned subsidiary Strides Pharma Global Pte. Limited, entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. to develop multiple nasal spray products for the US market across diverse therapeutic indications. Kenox provides formulation and development expertise in Orally Inhaled and Nasal Drug Products (OINDPs), combining its technical capabilities with Strides' manufacturing and commercial strengths. The collaboration aims to accelerate affordable, high-quality nasal spray medicines for patients in the US.

Scale indicators2 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Hovione: Hovione is a CDMO with strong capabilities in inhaled and nasal drug product development and manufacturing, including particle engineering and formulation. Comparable to Kenox as a specialized respiratory/nasal development partner serving pharmaceutical clients from clinical through commercial supply.
• Aptar Pharma: Aptar Pharma is a leading provider of drug delivery systems and CDMO services for inhaled, nasal, and ophthalmic products. Directly comparable to Kenox as both serve the OINDP CDMO niche, though Aptar operates at a substantially larger scale across commercial manufacturing and device platforms.
• Vectura Group: Vectura is an inhaled drug delivery specialist offering formulation development, device platforms, and manufacturing for inhaled therapeutics. Comparable to Kenox in serving OINDP-focused clinical and commercial programs across respiratory indications.
• Kindeva Drug Delivery: Kindeva Drug Delivery (formerly 3M Drug Delivery Systems spinoff) is a CDMO specializing in inhaled drug product development and manufacturing. Comparable to Kenox as a specialized OINDP CDMO serving pharmaceutical clients across clinical and commercial stages.
• Nemera: Nemera is a drug delivery device company offering development and manufacturing solutions for nasal, pulmonary, and ophthalmic products. Comparable to Kenox in serving the OINDP drug-device combination niche with custom development services.

Broad incumbents

• Catalent: Catalent is a large global CDMO offering a broad portfolio including inhaled and nasal drug delivery, soft mist inhalers, and clinical supply services. Relevant as a much larger incumbent that overlaps with Kenox's clinical-stage OINDP development and manufacturing offerings.
• Lonza Capsules & Health Ingredients: Lonza is a major global CDMO with inhalation development and manufacturing capabilities alongside its broader biologics and small-molecule services. Comparable to Kenox as a competing CDMO offering OINDP development services, though at far greater scale.
• Recipharm: Recipharm is a global CDMO providing development and manufacturing services including inhalation and nasal capabilities. Comparable as an established CDMO offering OINDP-adjacent services with broader dosage form coverage.
• 3M Drug Delivery Systems: 3M's Drug Delivery Systems division provides inhalation and transdermal drug delivery technologies including device platforms and contract services. Comparable to Kenox as a much larger incumbent offering OINDP-relevant drug-device combination solutions.

Others

• Copley Scientific: Copley Scientific supplies testing equipment and services for inhaled and nasal drug product development, including in vitro bioequivalence apparatus. Comparable to Kenox as an ecosystem participant serving the same OINDP regulatory and analytical testing workflows.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kenox-pharmaceuticals-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kenox Pharmaceuticals